Apparent mineralocorticoid excess in Israel: a case series and literature review
European Journal of Endocrinology · 02.05.2024 · 190 (5) · 347-353
DOI: 10.1093/ejendo/lvae049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Endocrinology, online erschienen am 23.04.2024. Verfasst von Asaf Lebel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Nephrology Unit, HaEmek Medical Center, Afula 1834111, Israel. Hauptthemen laut MEDLINE: Mineralocorticoid Excess Syndrome, Apparent. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background and Objective Apparent mineralocorticoid excess (AME) syndrome is an ultra-rare autosomal-recessive tubulopathy, caused by mutations in HSD11B2, leading to excessive activation of the kidney mineralocorticoid receptor, and characterized by early-onset low-renin hypertension, hypokalemia, and risk of chronic kidney disease (CKD). To date, most reports included few patients, and none described patients from Israel. We aimed to describe AME patients from Israel and to review the relevant literature.
Design
Retrospective cohort study.
Methods
Clinical, laboratory, and molecular data from patients’ records were collected.
Results
Five patients presented at early childhood with normal estimated glomerular filtration rate (eGFR), while 2 patients presented during late childhood with CKD. Molecular analysis revealed 2 novel homozygous mutations in HSD11B2. All patients presented with severe hypertension and hypokalemia. While all patients developed nephrocalcinosis, only 1 showed hypercalciuria. All individuals were managed with potassium supplements, mineralocorticoid receptor antagonists, and various antihypertensive medications. One patient survived cardiac arrest secondary to severe hyperkalemia. At last follow-up, those 5 patients who presented early exhibited normal eGFR and near-normal blood pressure, but 2 have hypertension complications. The 2 patients who presented with CKD progressed to end-stage kidney disease (ESKD) necessitating dialysis and kidney transplantation.
Conclusions
In this 11-year follow-up report of 2 Israeli families with AME, patients who presented early maintained long-term normal kidney function, while those who presented late progressed to ESKD. Nevertheless, despite early diagnosis and management, AME is commonly associated with serious complications of the disease or its treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Nephrology Unit, HaEmek Medical Center, Afula 1834111, Israel.
- Pediatric Nephrology Unit, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9103102, Israel.
- Pediatric Department B, HaEmek Medical Center, Afula 1834111, Israel.
- Technion Faculty of Medicine, Pediatric Nephrology Institute, Ruth Children's Hospital, Rambam Health Care Campus, Haifa 3109601, Israel.
ORCID-Profile: Asaf Lebel
Zitieren
APA
Lebel, A., Ben Shalom, E., Mokatern, R., Halevy, R., Zehavi, Y., & Magen, D. (2024). Apparent mineralocorticoid excess in Israel: a case series and literature review. European Journal of Endocrinology, 190(5), 347-353. https://doi.org/10.1093/ejendo/lvae049
Vancouver
Lebel A, Ben Shalom E, Mokatern R, Halevy R, Zehavi Y, Magen D. Apparent mineralocorticoid excess in Israel: a case series and literature review. European Journal of Endocrinology. 2024;190(5):347-353. doi:10.1093/ejendo/lvae049
BibTeX
@article{Lebel2024,
author = {Lebel, Asaf and Ben Shalom, Efrat and Mokatern, Rozan and Halevy, Raphael and Zehavi, Yoav and Magen, Daniela},
title = {Apparent mineralocorticoid excess in Israel: a case series and literature review},
journal = {European Journal of Endocrinology},
year = {2024},
volume = {190},
number = {5},
pages = {347--353},
doi = {10.1093/ejendo/lvae049}
}
EUVIMED